TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7701040
Drug: Methadone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (50 mg oral, max 90 mg), average dose 66.6 mg
Study: 3115632
Drug: Melatonin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (500 mg at -60 min and at -30 min)
Study: 3115632
Drug: Melatonin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (500 mg) prior to GRF 1-44 (1 micrograms/kg i.v. at 0 min)
Study: 28224818
Drug: Low-dose docosahexaenoic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose docosahexaenoic acid (DHA) (260 mg or 520 mg/day)
Study: 27593174
Drug: Thrice-weekly insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrice-weekly insulin degludec (IDeg) injected at twice the once-daily dose before lunch on Monday, Wednesday, and Friday
Study: 24850107
Drug: ITM 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITM 0.2 mg
Study: 24850107
Drug: ITM 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITM 0.5 mg
Study: 24850107
Drug: ITM 1
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ITM 1 mg
Study: 21226953
Drug: Cilostazol and
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol and Probucol combination therapy
Study: 24705623
Drug: Cilostazol monotherapy
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol monotherapy
Study: 18316488
Drug: Transcatheter PFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter PFO closure with the STARFlex implant
Study: 1483490
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human calcitonin (hCT)
Study: 3893112
Drug: Methylprednisolone 2
Normalized name: methylprednisolone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 2 mg/kg per day intravenously (n = 39)
Study: 3893112
Drug: Cyclosporine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (12 to 15 mg/kg per day orally or 3 to 5 mg/kg per day intravenously) (n = 38)
Study: 22747752
Drug: Synbiotic formulation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic formulation (Synbiotic 2000®) containing 4 strains of probiotic bacteria (10^10 each) plus 4 nondigestible, fermentable dietary fibers (2.5 g each) daily for 4 weeks
Study: 22747752
Drug: Fiber-only placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-only placebo formulation
Study: 22747752
Drug: Synbiotic formulation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic formulation (Synbiotic 2000®)
Study: 8562299
Drug: Felbamate 1200
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate 1200 mg every 12 h with vigabatrin 1000 mg every 12 h
Study: 8562299
Drug: Vigabatrin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 1000 mg every 12 h with felbamate 1200 mg every 12 h
Study: 466335
Drug: Intravenous on-demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous on-demand fentanyl infusion
Study: 466335
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections of bupivacaine
Study: 28468648
Drug: Counseling plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling plus Expedited Partner Therapy (EPT) with cefixime 400 mg/azithromycin 1 g for up to five recent partners; n=89.
Study: 22664861
Drug: Rapid enteral
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid enteral feeding advancement (30 mL/kg/d)
Study: 22664861
Drug: Slow enteral
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow enteral feeding advancement (20 mL/kg/d)
Study: 21654257
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol intake (≤14 g/day)
Study: 21654257
Drug: Heavy alcohol
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy alcohol intake (>14 g/day)
Study: 16942571
Drug: Drugs only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs only (Control)
Study: 2648792
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acetylsalicylic acid (ASA) once daily
Study: 30880405
Drug: Antidepressants (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (three types, unspecified)
Study: 21530211
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFA) 2.4 g
Study: 11130217
Drug: LTG 100
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG 100 mg with steady‐state BUP 150 mg twice/day
Study: 11130217
Drug: LTG 100
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG 100 mg
Study: 9316823
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (0.06-2.00 mg/kg infused over 2 hr)
Study: 8287864
Drug: Allopurinol in
Normalized name: allopurinol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol in the cardioplegic solution
Study: 8287864
Drug: Trimetazidine pre-treatment
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine pre-treatment and addition to the cardioplegic solution
Study: 3817280
Drug: Tioconazole cream
Normalized name: Tioconazole
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tioconazole cream 1%
Study: 31784988
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (ITB) treatment
Study: 28744742
Drug: non-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-treatment
Study: 25465324
Drug: BMS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS plus drug coated balloon (DCB)
Study: 23127306
Drug: oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hygiene instruction and chlorhexidine mouthrinse
Study: 23127306
Drug: oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hygiene instruction, chlorhexidine mouthrinse, and assisted brushing
Study: 23127306
Drug: oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hygiene instruction alone
Study: 21047828
Drug: NVP200 (nevirapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP200 (nevirapine initiation by dose escalation)
Study: 21047828
Drug: NVP400 (nevirapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP400 (nevirapine initiation at 200 mg twice daily)
Study: 18799723
Drug: CHVP+I (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHVP+I (chemotherapy plus interferon)
Study: 1750722
Drug: Terfenadine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 120 mg twice a day
Study: 7127660
Drug: Oral adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral adjuvant razoxane (ICRF-159)
Study: 28576557
Drug: Ethanol lock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol lock therapy (ELT)
Study: 24183730
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training/behavioral therapy
Study: 17549054
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma (FFP) infusions
Study: 17549054
Drug: No fresh
Normalized name: Aveeno Fresh Greens Blend Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fresh frozen plasma (FFP) infusions
Study: 10879067
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for atherosclerosis; specific interventions not detailed in the abstract.
Study: 8445289
Drug: Thromboxane synthase
Normalized name: Thromboxane synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboxane synthase inhibitor (FCE 22178, 400 mg two or three times per day)
Study: 16356945
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to a genitourinary medicine clinic
Study: 10799728
Drug: Post-mastectomy irradiation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-mastectomy irradiation plus systemic treatment
Study: 11384568
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% three times daily
Study: 19697094
Drug: Interpersonal Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Psychotherapy group (IPT-G)
Study: 17242805
Drug: Nizatidine 600
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine 600 mg
Study: 12809451
Drug: Morning insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning insulin glargine + 3 mg glimepiride
Study: 12809451
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin glargine + 3 mg glimepiride
Study: 12809451
Drug: Bedtime NPH
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime NPH insulin + 3 mg glimepiride
Study: 16513202
Drug: Morning insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning insulin glargine
Study: 12809451
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin glargine
Study: 10810461
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocols for osteosarcoma (same as used for adolescents)
Study: 10810461
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocols for osteosarcoma
Study: 8861695
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 10 mg/kg of phenytoin (group A, n = 10)
Study: 8861695
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 15 mg/kg of phenytoin (group B, n = 10)
Study: 8861695
Drug: PHT maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT maintenance treatment (250 mg, i.v., every 8 hours)
Study: 27387676
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy followed by tumor resection
Study: 22124712
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration prior to EEG recording
Study: 22124712
Drug: No melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No melatonin administration prior to EEG recording
Study: 16198658
Drug: Cyclosporine 100
Normalized name: cyclosporine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 100 mg
Study: 10439743
Drug: Neostigmine (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.07 mg/kg) with glycopyrrolate (0.01 mg/kg) given 5 min after relaxant
Study: 38439
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (amounts: 150, 180, 210, 240 ml) ingested with each meal during a 12-day period.
Study: 25886499
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education + 12-week supervised exercise therapy program
Study: 19594771
Drug: Control (non-statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-statin treatment)
Study: 15697105
Drug: 35 microg
Normalized name: Ethinyl estradiol 35 microgram and norethindrone 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 microg Ethinylestradiol/2 mg Cyproterone Acetate (Diane 35, Schering) for 3 months
Study: 15697105
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Medroxyprogesterone Acetate (MPA) x 10 days every month for 3 months (control group)
Study: 12172440
Drug: Fixed-dose low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed-dose low molecular weight heparin (LMWH) Certoparin, 2 x 8000 aXa IU
Study: 9596473
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine 1
Study: 9596473
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine 2
Study: 2539763
Drug: Quinapril (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10, 20, and 40 mg/day)
Study: 2539763
Drug: Enalapril (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10, 20, and 40 mg/day)
Study: 81154
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg daily
Study: 31058457
Drug: Self-monitoring urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring urinary salt excretion measurement device for 4 weeks
Study: 23218853
Drug: Nitroprusside gel
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nitroprusside gel (10 mg, 1 mL)
Study: 23218853
Drug: Nitroprusside gel
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nitroprusside gel
Study: 15308353
Drug: Men D
Normalized name: Glove Ladies/Men Dermal Large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men D (2 doses at 3 and 9 months)
Study: 15308353
Drug: Men D
Normalized name: Glove Ladies/Men Dermal Large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men D (single dose in infancy)
Study: 10958046
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg/day (400 mg/day from 1st to 3rd day, 800 mg/day from 4th to 6th day, 1200 mg/day from 7th day)
Study: 8623963
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg IV ephedrine
Study: 8623963
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg IV ephedrine
Study: 1836780
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same emulsion without active drug)
Study: 6122755
Drug: Intestinal lavage
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal lavage with 18 L of normal saline administered via a jejunal tube over a period of 2 hours
Study: 6122755
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving similar treatment without lavage
Study: 26720458
Drug: Lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (10 mg) and antioxidant supplement
Study: 26720458
Drug: Lutein and
Normalized name: ICaps Lutein and Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein and antioxidant supplement in combination with PUFA
Study: 24617431
Drug: Methotrexate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (7.5 mg weekly)
Study: 24617431
Drug: Ciclosporin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (2.5 mg kg(‐1) daily)
Study: 20048271
Drug: Cultural competency
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultural competency training and monthly race-stratified performance reports
Study: 15701591
Drug: Calcipotriol/betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/betamethasone dipropionate ointment (Daivobet/Dovobet), applied once daily for 4 weeks.
Study: 10520159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dental treatment plus amphotericin B
Study: 7781398
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus concurrent radiation therapy
Study: 31234840
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention including identification of drug related problems, drug interactions, change in dose, frequency and therapy switches, and non-pharmacological intervention consisting of diet, lifestyle and behavior counseling
Study: 29217757
Drug: Elamipretide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elamipretide (0.25 mg·kg‐1·h‐1)
Study: 23803594
Drug: Neostigmine 10
Normalized name: neostigmine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 10 µg kg(‐1)
Study: 23803594
Drug: Neostigmine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 20 µg kg(‐1)
Study: 23803594
Drug: Neostigmine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 30 µg kg(‐1)
Study: 16330915
Drug: Clopidogrel in
Normalized name: Product containing clopidogrel in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel in combination with aspirin
Study: 16330915
Drug: Combination antiplatelet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiplatelet therapy with clopidogrel and aspirin
Study: 7806018
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with non-insulin-dependent diabetes mellitus
Study: 3286064
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin concentration
Study: 7806018
Drug: 30-min insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-min insulin increment
Study: 51576
Drug: Menaquinone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone therapy alone
Study: 51576
Drug: Menaquinone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone therapy with hyposensitization therapy
Study: 30111240
Drug: Tenease therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenease therapy (mechanical high-frequency vibration device)
Study: 30111240
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (physiotherapy, activity modification, and analgesia)
Study: 19861956
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) for 12 weeks
Study: 17593012
Drug: Topical pranoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pranoprofen 0.1%
Study: 11972097
Drug: Total transfusion
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total transfusion volume of more than 250 mL/kg
Study: 9504437
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline orally at 0100 h
Study: 9504437
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline orally at 0700 h
Study: 9504437
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline orally at 1300 h
Study: 9504437
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline orally at 1900 h
Study: 8699518
Drug: Threaded, hydroxylapatite-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threaded, hydroxylapatite-coated implant
Study: 132695
Drug: Feprazone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feprazone, 200 mg t.d.s.
Study: 132695
Drug: Indomethacin, 25
Normalized name: Indomethacin, 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 25 mg t.d.s. rising to 50 mg t.d.s.
Study: 29187388
Drug: Almond diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond diet (ALD) - 42.5 g/d of almonds
Study: 29187388
Drug: Chocolate diet
Normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocolate diet (CHOC) - 18 g/d of cocoa powder and 43 g/d of dark chocolate
Study: 25194428
Drug: Chamomile tea
Normalized name: Chamomile Tea
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile tea (3 g/150 mL hot water) three times per day immediately after meals for 8 weeks
Study: 21984399
Drug: Astaxanthin (AST)
DrugBank: Astaxanthin (DB06543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (AST) 4 mg/d for 28 days
Study: 1636574
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1.5 million units/60 minutes)
Study: 1636574
Drug: Intravenous anistreplase
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anistreplase (30 units/2 to 5 minutes)
Study: 1636574
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase or anistreplase
Study: 31914443
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy (AIT) plus pharmacological treatment
Study: 24595228
Drug: Sevoflurane treatment
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane treatment (both intramyocardial and systemic)
Study: 19939196
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral folic acid supplement
Study: 10683816
Drug: DHA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (1.5 g DHA per day for 9 weeks)
Study: 10683816
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 capsules of mixed plant oil per day for 9 weeks)
Study: 6130079
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 mg t.i.d.)
Study: 6130079
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg t.i.d.)